Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Immune-Related Adverse Events in Patients with Cancer: From Bench to...
share announcement

Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3572

Special Issue Editors

Dr. Konstantinos Syrigos

E-Mail Website
Guest Editor
Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer; lung cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Dr. Ioannis Vathiotis

E-Mail Website
Guest Editor
Third Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: cancer; lung cancer; head and neck cancer; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Dr. Nikolaos K. Syrigos

E-Mail Website
Guest Editor
Breast Oncology Center – Translational Hub, Dana-Farber/Harvard Cancer Center, Boston, MA 02215, USA
Interests: cancer; breast cancer; immunotherapy; immune-related adverse events

Special Issue Information

Dear Colleagues,

Since 2011, immunotherapy has altered the treatment landscape of many tumor types. The recent combination with different treatment modalities as well as development in the curative setting has caused the use of immune checkpoint inhibitors to rise exponentially. Despite documented benefits, immune checkpoint inhibition is associated with a novel spectrum of toxicities termed immune-related adverse events (irAEs); these events are inflammatory in nature, can occur at any time during the patient’s treatment course, and affect essentially every organ system. 

Although there is growing consensus regarding the management of irAEs in cancer, more work is required to elucidate their exact mechanism of action, identify predictive biomarkers, and understand the mechanisms of steroid resistance with direct therapeutic implications.  

Hosting perspectives from distinct subspecialties involved in preclinical as well as clinical research on irAEs, this Special Issue aims to provide a comprehensive summary of current knowledge on immunotherapy toxicity in patients with cancer. We also aim to present cutting-edge research that will shed light on various aspects of this evolving field, including but not limited to pathophysiology, taxonomy, and association with immunotherapy outcomes. A better understanding of irAEs will facilitate collaboration among different subspecialties and ultimately improve the management of immunotherapy toxicity in patients with cancer. We invite you to submit your work, including original articles, expert reviews, and commentaries on this important subject.

Dr. Konstantinos Syrigos
Dr. Ioannis Vathiotis
Dr. Nikolaos K. Syrigos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • immunotherapy
  • immune-related adverse events
  • irAE
  • immune checkpoint inhibitors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

18 pages, 2338 KiB  
Article
T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
by Magdalena Absmaier-Kijak, Caterina Iuliano, Susanne Kaesler, Tilo Biedermann, Christian Posch and Knut Brockow
Cancers 2024, 16(6), 1226; https://doi.org/10.3390/cancers16061226 - 20 Mar 2024
Viewed by 642
Abstract
Immune checkpoint inhibition (ICI) improves outcomes in melanoma patients, but associated T-cell activation frequently leads to immune-related cutaneous adverse events (cutAEs). To dynamically identify T-cell subtypes and immune signatures associated with cutAEs, a pilot study was performed in stage III-IV melanoma patients using [...] Read more.
Immune checkpoint inhibition (ICI) improves outcomes in melanoma patients, but associated T-cell activation frequently leads to immune-related cutaneous adverse events (cutAEs). To dynamically identify T-cell subtypes and immune signatures associated with cutAEs, a pilot study was performed in stage III-IV melanoma patients using blood samples for flow cytometry and cytokine analysis. Blood samples were taken from patients before initiation of ICI (naive), at the onset of a cutAE, and after 6 months of ICI treatment. Overall, 30 patients were treated either with anti-PD1 monotherapy or with anti-PD-1/anti-CTLA-4 combination therapy. Flow cytometry analysis of PBMCs showed that ICI induced an overall shift from a Th2 towards a Th1 profile. Twelve patients (40%) developed cutAEs, which were associated with increased Th22 cells and Th17 cells, supported by a tendency to have elevated Th17/Th22-associated cytokines such as IL-17A, IL-22 and IL-23 levels in the plasma. Cytokine signatures specific for urticaria and T-cell-mediated cutAEs were identified in the plasma of patients by a bead-based assay. IL-10 was elevated in non-responders and, interestingly, during cutAEs. In conclusion, we identified distinct immune signatures based on the Th17/Th22 pathway in cutAEs, both in PBMCs and plasma. In addition, our finding of upregulated IL-10 during cutAEs supports the notion of treating these patients early and adequately to avoid implications for the overall outcome. Full article
(This article belongs to the Special Issue Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside)
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 660 KiB  
Systematic Review
Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
by Ioannis P. Trontzas, Ioannis A. Vathiotis, Konstantinos G. Kyriakoulis, Amalia Sofianidi, Zoi Spyropoulou, Andriani Charpidou, Elias A. Kotteas, Konstantinos N. Syrigos and ImmunoTTS Collaborative Group
Cancers 2023, 15(9), 2637; https://doi.org/10.3390/cancers15092637 - 06 May 2023
Cited by 2 | Viewed by 2482
Abstract
Background: There are emerging reports of Takotsubo syndrome (TTS) in cancer patients treated with immune checkpoint inhibitors (ICIs); however, the association of the two remains uncertain. Methods: A systematic literature review was performed in the PubMed database and web sources (Google Scholar) according [...] Read more.
Background: There are emerging reports of Takotsubo syndrome (TTS) in cancer patients treated with immune checkpoint inhibitors (ICIs); however, the association of the two remains uncertain. Methods: A systematic literature review was performed in the PubMed database and web sources (Google Scholar) according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. Case reports/series or studies including cancer patients treated with ICIs and presenting with TTS were considered. Results: Seventeen cases were included in the systematic review. Most patients were males (59%) with median age of 70 years (30–83). Most common tumor types were lung cancer (35%) and melanoma (29%). Most patients were on first-line immunotherapy (35%) and after the first cycle (54%) of treatment. The median time on immunotherapy at the time of TTS presentation was 77 days (1–450). The most used agents were pembrolizumab and the combination of nivolumab–ipilimumab (35%, respectively). Potential stressors were recognized in 12 cases (80%). Six patients (35%) presented with concurrent cardiac complications. Corticosteroids were used in the management of eight patients (50%). Fifteen patients (88%) recovered from TTS, two patients (12%) relapsed, and one patient died. Immunotherapy was reintroduced in five cases (50%). Conclusion: TTS may be associated with immunotherapy for cancer. Physicians should be alert for TTS diagnosis in any patient with myocardial infarction-like presentation under treatment with ICIs. Full article
(This article belongs to the Special Issue Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop